Voyager Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)(1) Financial Statements.
| | Pages | |
| Report of independent registered public accounting firm (PCAOB ID 42) | | F-1 |
|---|---|---|
| Consolidated Balance Sheets | | F-3 |
| Consolidated Statements of Operations and Comprehensive (Loss) Income | | F-4 |
| Consolidated Statements of Stockholders’ Equity | | F-5 |
| Consolidated Statements of Cash Flows | | F-6 |
| Notes to consolidated financial statements | | F-7 |
(a)(2) Financial Statement Schedules.
All schedules have been omitted because they are not required or because the required information is given in the Consolidated Financial Statements or Notes thereto set forth under Item 8 above.
(a)(3) Exhibits.
See the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The exhibits listed in the Exhibit Index below are filed or incorporated by reference as part of this Annual Report on Form 10-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.